Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 30.69
OPXA's Cash-to-Debt is ranked lower than
51% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OPXA: 30.69 )
Ranked among companies with meaningful Cash-to-Debt only.
OPXA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 19.93 Max: No Debt
Current: 30.69
Equity-to-Asset 0.70
OPXA's Equity-to-Asset is ranked higher than
53% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPXA: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
OPXA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1246  Med: 0.35 Max: 0.78
Current: 0.7
-1246
0.78
Piotroski F-Score: 3
Altman Z-Score: -76.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -232.61
OPXA's Operating Margin % is ranked lower than
61% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OPXA: -232.61 )
Ranked among companies with meaningful Operating Margin % only.
OPXA' s Operating Margin % Range Over the Past 10 Years
Min: -1184.59  Med: -707.1 Max: -232.61
Current: -232.61
-1184.59
-232.61
Net Margin % -232.30
OPXA's Net Margin % is ranked lower than
61% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. OPXA: -232.30 )
Ranked among companies with meaningful Net Margin % only.
OPXA' s Net Margin % Range Over the Past 10 Years
Min: -1314.6  Med: -826.78 Max: -232.3
Current: -232.3
-1314.6
-232.3
ROE % -147.95
OPXA's ROE % is ranked lower than
86% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OPXA: -147.95 )
Ranked among companies with meaningful ROE % only.
OPXA' s ROE % Range Over the Past 10 Years
Min: -654.63  Med: -135.24 Max: -32.36
Current: -147.95
-654.63
-32.36
ROA % -95.84
OPXA's ROA % is ranked lower than
85% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. OPXA: -95.84 )
Ranked among companies with meaningful ROA % only.
OPXA' s ROA % Range Over the Past 10 Years
Min: -345.19  Med: -91.83 Max: -24.27
Current: -95.84
-345.19
-24.27
ROC (Joel Greenblatt) % -1124.33
OPXA's ROC (Joel Greenblatt) % is ranked lower than
63% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. OPXA: -1124.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPXA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1800  Med: -994.37 Max: -410.49
Current: -1124.33
-1800
-410.49
3-Year Revenue Growth Rate -15.10
OPXA's 3-Year Revenue Growth Rate is ranked lower than
71% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OPXA: -15.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPXA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -15.1
Current: -15.1
3-Year EBITDA Growth Rate -47.20
OPXA's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. OPXA: -47.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPXA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.7 Max: 43.2
Current: -47.2
0
43.2
3-Year EPS without NRI Growth Rate -49.60
OPXA's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OPXA: -49.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPXA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -42.7 Max: 51.8
Current: -49.6
0
51.8
GuruFocus has detected 3 Warning Signs with Opexa Therapeutics Inc $OPXA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPXA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:ISCO, OTCPK:BITRF, OTCPK:PPCB, OTCPK:CTTC, OTCPK:MDFZF, OTCPK:AEMAF, OTCPK:IMMG, OTCPK:SGBI, OTCPK:TSOI, OTCPK:VXLLF, OTCPK:BIEI, OTCPK:KNBIF, AMEX:APHB, OTCPK:TIKRF, OTCPK:RGBP, OTCPK:CTBO, OTCPK:GNBT, OTCPK:AURX, OTCPK:ENUM, AMEX:IMUC » details
Traded in other countries:P6NP.Germany,
Headquarter Location:USA
Opexa Therapeutics Inc is a biopharmaceutical company engaged in developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica.

Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.

Ratios

vs
industry
vs
history
PB Ratio 2.13
OPXA's PB Ratio is ranked higher than
75% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. OPXA: 2.13 )
Ranked among companies with meaningful PB Ratio only.
OPXA' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.59 Max: 11.14
Current: 2.13
0.96
11.14
PS Ratio 2.03
OPXA's PS Ratio is ranked higher than
88% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. OPXA: 2.03 )
Ranked among companies with meaningful PS Ratio only.
OPXA' s PS Ratio Range Over the Past 10 Years
Min: 1.39  Med: 10.86 Max: 77.02
Current: 2.03
1.39
77.02
Current Ratio 3.74
OPXA's Current Ratio is ranked lower than
53% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OPXA: 3.74 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.16 Max: 13.24
Current: 3.74
0.01
13.24
Quick Ratio 3.74
OPXA's Quick Ratio is ranked higher than
50% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OPXA: 3.74 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.16 Max: 13.24
Current: 3.74
0.01
13.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -30.40
OPXA's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. OPXA: -30.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPXA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -393.2  Med: -70.1 Max: 0
Current: -30.4
-393.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.38
OPXA's Price-to-Net-Cash is ranked higher than
84% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. OPXA: 2.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OPXA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.08  Med: 5.92 Max: 217.12
Current: 2.38
1.08
217.12
Price-to-Net-Current-Asset-Value 2.14
OPXA's Price-to-Net-Current-Asset-Value is ranked higher than
86% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OPXA: 2.14 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OPXA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.99  Med: 4.73 Max: 122.88
Current: 2.14
0.99
122.88
Price-to-Tangible-Book 2.14
OPXA's Price-to-Tangible-Book is ranked higher than
80% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. OPXA: 2.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPXA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 3.51 Max: 119.82
Current: 2.14
0.62
119.82
Price-to-Median-PS-Value 0.18
OPXA's Price-to-Median-PS-Value is ranked higher than
92% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. OPXA: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPXA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.09 Max: 7.11
Current: 0.18
0.18
7.11
Earnings Yield (Greenblatt) % -329.84
OPXA's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. OPXA: -329.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPXA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3255  Med: -148.5 Max: 5805
Current: -329.84
-3255
5805

More Statistics

Revenue (TTM) (Mil) $2.90
EPS (TTM) $ -0.94
Beta1.89
Short Percentage of Float7.74%
52-Week Range $0.50 - 4.93
Shares Outstanding (Mil)7.66

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.89 -1.73 -0.09
EPS without NRI ($) -1.89 -1.73 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12 2016 
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 May 10 2016 
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Apr 27 2016 
Opexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update Mar 15 2016 
Opexa Launches Restructuring Initiative to Focus Use of Resources Ahead of Key Phase 2 Data Expected Mar 02 2016 
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference Jan 28 2016 
Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc. Sep 02 2015 
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Opexa Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update May 12 2017
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017 Mar 30 2017
Opexa Therapeutics Reports 2016 Year End Financial Results and Provides Corporate Update Mar 28 2017
Opexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for... Feb 01 2017
These 5 Stocks Under $10 Could Explode Higher Soon Jan 12 2017
ETFs with exposure to Opexa Therapeutics, Inc. : December 23, 2016 Dec 23 2016
ETFs with exposure to Opexa Therapeutics, Inc. : November 18, 2016 Nov 18 2016
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Biotech Movers on Thursday: Cempra Inc (CEMP) And Opexa Therapeutics Inc (OPXA) Nov 03 2016
Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of... Nov 02 2016
6 Companies That Destroyed Shareholders Last Week Oct 29 2016
GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on... Oct 28 2016
Is This the Beginning of the End of Opexa? Oct 28 2016
Opexa Therapeutics Announces Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary... Oct 28 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : October 17, 2016 Oct 17 2016
Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference Sep 07 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : August 12, 2016 Aug 12 2016
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}